New DNA Test Could Revolutionize Diagnosis of Rare Diseases
A long-read DNA sequencing technology developed by researchers at the Broad Institute of MIT and Harvard has shown potential to replace 15 existing diagnostic tests for rare genetic disorders, according to a study published in *Nature Genetics* on June 12, 2024. The test, which analyzes entire genetic sequences in a single assay, reduces the need for multiple specialized tests that have historically been time-consuming and costly.
How the Technology Works
Unlike traditional short-read sequencing, which fragments DNA into small pieces for analysis, long-read sequencing captures entire genes and regulatory regions in one go. This approach allows scientists to detect complex mutations, such as large deletions or structural variations, that are often missed by conventional methods. The Broad Institute team reported that the test identified pathogenic variants in 42% of cases where prior testing had failed to yield a diagnosis.
Implications for Patients and Clinicians
The technology could significantly shorten the “diagnostic odyssey” for patients with rare diseases, a term used to describe the prolonged and often frustrating process of identifying a genetic cause. “This test offers a more comprehensive view of the genome, which is critical for diagnosing conditions that have eluded traditional methods,” said Dr. Wendy Chung, a geneticist at Columbia University, in a statement.
Cost and Accessibility Concerns
While the test’s accuracy is promising, its high cost—estimated at $3,000 to $5,000 per patient—raises questions about accessibility. Current insurance coverage for long-read sequencing remains limited, according to a 2023 report by the American College of Medical Genetics. However, proponents argue that the technology’s efficiency could lower long-term healthcare costs by reducing the need for follow-up tests.
Comparison to Existing Methods
A 2022 study in *JAMA Pediatrics* found that short-read sequencing diagnosed only 25% of rare disease cases, compared to 42% with long-read methods. The new test also outperformed targeted gene panels, which typically analyze 10–50 genes at a time. “It’s like comparing a mosaic to a full painting,” said Dr. Sarah Ng, a molecular geneticist at the University of California, San Francisco. “Long-read sequencing reveals the entire picture.”
Next Steps and Challenges
The Broad Institute team plans to expand trials to include diverse populations, as most genetic studies have historically focused on individuals of European descent. Regulatory approval from the FDA is also pending, though the agency has expressed interest in accelerating reviews for innovative diagnostic tools.
Why This Matters
The development aligns with broader trends in precision medicine, which aims to tailor treatments to individual genetic profiles. A 2021 review in *The New England Journal of Medicine* highlighted the potential of long-read sequencing to transform care for rare diseases, which affect 350 million people globally. However, experts caution that widespread adoption will require addressing both financial and educational barriers for healthcare providers.
For now, the test remains available primarily through research programs and specialized clinics. As the technology evolves, its impact on rare disease diagnosis could reshape the landscape of genetic medicine.
Keep reading